The Czech Health Research Council, on behalf of the Ministry of Health, from September 2023, organises the agenda for the involvement of Czech scientists in the European Partnerships in Healthcare. These partnerships are a key tool for the implementation of the EU's 9th Framework Programme for Research, Development and Innovation "Horizon Europe". Participation in the European Partnerships represents a unique opportunity for the Czech Republic to collaborate in research, development and innovation activities at a pan-European level.
In December 2023, AZV ČR organised a seminar to present a basic insight into European partnerships, including their definition, types, conditions of involvement or funding modalities. At the same time, the first working version of the methodology was presented, which describes in more detail the steps from the actual establishment of European Partnerships to the launch and launch of co-funded calls, specifies the conditions and defines the general rules and procedures for the implementation of European Partnerships.
Presentation on European Partnerships for Health
Methodology on European Partnerships - 2nd working version (as of 1 November 2024)
Methodology on European Partnerships - 1st working version
European Partnerships are a "new generation" of cooperation that make a significant contribution to achieving EU policy priorities, replacing previous forms of partnerships such as ERA-NET Co-fund or Joint Programming Initiatives (JPIs). There are three types of partnerships - co-funded, co-programmed and institutionalised.
Within the 1. Strategic Plan (2021-2024), 9 European Partnerships in Healthcare have been proposed:
*European Rare Diseases Research Alliance (ERDERA) - co-funded by
*One Health Antimicrobial Resistance (OH AMR) - co-funded
*Personalised Medicine (PerMed) - co-funded
*Assessment of Risk from Chemicals (PARC) - co-funded
*ERA for Health Research (ERA4Health) - co-funded
*Transforming Health and Care Systems (THCS) - co-funded
*Pandemic Preparedness (BE-READY) - co-funded
*Global Health (EDCTP 3) - Institutionalized
*Innovative Health Initiative Joint Undertaking (IHI JU) - institutionalized
On the basis of the new findings and ongoing discussions, the Czech Republic will participate in 6 co-funded European Partnerships through AZV ČR :
* European Rare Diseases Research Alliance (ERDERA)
The aim of the partnership is to coordinate and fund transnational research to highly integrative and community-driven "in-house" activities in the field of rare diseases. These include innovative strategies for effective exploitation of research results, EU clinical trial readiness activities, optimisation of research infrastructures and resources, including networking, training and dissemination of information.
* One Health Antimicrobial Resistance (OH AMR)
The aim of the partnership is to coordinate and align activities and funding in the field of antimicrobial resistance both between countries and with the European Commission. It is also key to facilitate coherence between European countries at the level of different organisations and governmental institutions responsible for different aspects of antimicrobial resistance (e.g. human health, agriculture, environment, industry, finance).
* Personalised Medicine (PerMed)
The aim of the partnership is to improve outcomes in sustainable healthcare systems through research, development, innovation and the implementation of personalised medicine approaches for the benefit of patients and society as a whole.
* ERA for Health Research (ERA4Health)
The aim of the partnership is flexible joint planning of research agendas that will effectively coordinate most funding organisations, including smaller providers, across the EU. By effectively linking public health research actors in the ERA, a common funding strategy for best practice in priority areas of different health interventions addressing important public health needs will be designed and implemented.
* Transforming Health and Care Systems (THCS)
The aim of the partnership is to facilitate the transition to more sustainable, resilient, innovative and quality patient-centred health and care systems. At the same time, it is important to bring together a range of European, national, regional and international scientific resources to more effectively address similar challenges facing healthcare systems in Europe and beyond. Another objective is to facilitate the exchange of information and best practices between countries, to connect institutional stakeholders and to engage regional health and healthcare ecosystems.
* Pandemic Preparedness (BE-READY)
The partnership aims to improve the EU's preparedness to anticipate and respond to emerging infectious health threats, focusing on research and innovation in health and biotechnology. The partnership will be implemented in two phases. The first phase will focus primarily on how clinical trials are designed and conducted in the EU to address public health emergencies, including new approaches such as computer modelling. The duration of the first phase is set at 3 years and the second phase at 4 years.
If you have any questions, please do not hesitate to contact the European Partnerships in Healthcare Coordinator: